TPTX News and Press, Turning Point Therapeutics Inc. From 07/13/20

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief co...

Deals and Financings Ocumension [HK:1477], a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion (see story ). Founded in 2017, Ocumension was incubated by 6 Dimensions Capital...

Turning Point Therapeutics (NASDAQ: TPTX) on Tuesday licensed Greater China rights to its tyrosine kinase inhibitor, repotrectinib, to Zai Lab (NASDAQ: ZLAB) for $25 million in cash up front, plus up to  $151 million in development, regulatory and sales milestones, and tiered mid-to...

Turning Point Therapeutics ( TPTX +0.6% ) signs an agreement with Zai Lab ( ZLAB +4.3% ) for Turning Point’s lead drug candidate, repotrectinib for lung cancer. More news on: Turning Point Therapeutics, Inc., Zai Lab Limited, Healthcare stocks news, Read more ...

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...

Turning Point Therapeutics ( TPTX +1.9% ) announces encouraging results from preclinical studies evaluating lead drug repotrectinib, a tyrosine kinase inhibitor. Results showed that the combination of repotrectinib and proxy molecules for Amgen's AMG510 or Novartis' Mekinist (trametinib)...

SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today presented preclinical studies highlighting the potential for its lead drug candidate, ...

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate via webc...

Over the past week, the S&P 500 rose again by 2.75%, almost recovering from its YTD losses. With economies restarting, novel optimism about vaccines and better-than-feared job losses last week, the stock market is behaving very optimistically. Of course, the biggest reason for this strong ...